Cassava Sciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard Jon Barry
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7801 North Capital of Texas Highway Austin TX United States of America 78731
- IPO Date
- Jul 14, 2000
- CIK
- 0001069530
- Website
- cassavasciences.com
- Similar Companies
- Business
- Cassava Sciences, Inc. (NASDAQ: SAVA) is a clinical-stage biopharmaceutical company that develops novel treatments for central nervous system disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related epilepsy; its lead therapeutic candidate is simufilam, an oral small molecule drug that targets altered filamin A (FLNA) protein in the brain to restore normal function; its lead diagnostic candidate is SavaDx, an early-stage blood-based test to detect Alzheimer's disease. Founded in 1998 and headquartered in Austin, Texas, the company operates primarily in the United States with a focus on neurodegenerative and epilepsy-related conditions targeting patients with unmet medical needs in these areas. Recent strategic shifts include the discontinuation of Phase 3 Alzheimer's trials (RETHINK-ALZ and REFOCUS-ALZ) following topline data in late 2024 that failed to meet primary endpoints, a pivot to TSC-related epilepsy supported by a February 2025 license agreement with Yale University and positive preclinical studies with the TSC Alliance, key leadership appointments such as Dr. Angélique Bordey as SVP of Neuroscience and Dr. Jack Moore as SVP of Clinical Development alongside the addition of Dawn C. Bir as independent director, a 33% workforce reduction in Q1 2025 to cut costs, and plans to initiate a proof-of-concept clinical trial of simufilam in TSC-related epilepsy in the first half of 2026.
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Cassava Announces Agreement to Settle Securities Class Action Litigation
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold
Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround
Is the Future Bleak for SAVA Stock Following Another Setback?
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Cassava Sciences Reports 2024 Financial Results and Provides Business Update